title: Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury.
abstract: Injury of the arterial wall induces the formation of the neointima. This structure is generated by the growth of mitogenically activated smooth muscle cells of the arterial wall. The molecular mechanism underlying the formation of the neointima involves deregulated cell growth, primarily triggered by the injury of the arterial wall. The activated gene products transmitting the injury-induced mitogenic stimuli have been identified and inhibited by several means: transdominant negative expression vectors, antisense oligodeoxynucleotides, adenovirus-mediated gene transfer, antibodies and inactivating drugs. Results of our study show that local administration of 3',5'-cyclic AMP and phosphodiesterase-inhibitor drugs (aminophylline and amrinone) to rats markedly inhibits neointima formation after balloon injury in vivo and in smooth muscle cells in vitro. The growth inhibitory effect of aminophylline was completely reversed by the inhibition of cAMP-dependent protein kinase A (PKA). These findings indicate an alternative approach to the treatment of diseases associated with injury-induced cell growth of the arterial wall, as stimulation of cAMP signaling is pharmacologically feasible in the clinical setting.
authors.affiliation: Cattedra di Cardiologia, Universita degli Studi di Napoli Federico II, Naples, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Indolfi
authors.forename: E V
authors.initials: EV
authors.lastname: Avvedimento
authors.forename: E
authors.initials: E
authors.lastname: Di Lorenzo
authors.forename: G
authors.initials: G
authors.lastname: Esposito
authors.forename: A
authors.initials: A
authors.lastname: Rapacciuolo
authors.forename: P
authors.initials: P
authors.lastname: Giuliano
authors.forename: D
authors.initials: D
authors.lastname: Grieco
authors.forename: L
authors.initials: L
authors.lastname: Cavuto
authors.forename: A M
authors.initials: AM
authors.lastname: Stingone
authors.forename: I
authors.initials: I
authors.lastname: Ciullo
authors.forename: G
authors.initials: G
authors.lastname: Condorelli
authors.forename: M
authors.initials: M
authors.lastname: Chiariello
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000628:Aminophylline / Q000494:pharmacology; D000676:Amrinone / Q000494:pharmacology; D000818:Animals; D002339:Carotid Arteries; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006131:Growth Inhibitors / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects / Q000293:injuries / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D006131:Growth Inhibitors; D010726:Phosphodiesterase Inhibitors; D015124:8-Bromo Cyclic Adenosine Monophosphate; D000628:Aminophylline; D017868:Cyclic AMP-Dependent Protein Kinases; D000676:Amrinone